https://www.selleckchem.com/pr....oducts/10-dab-10-dea
003). The 5-year OS of patients with lymph node (LN) metastases and unknown primary site (UPM) was 45% vs. 21% of patients with synchronous LN metastasis. Patients with SLN tumour burden 1.0 mm was similar to the MLNM group (49% vs. 47%; p = 0.28. Conclusions Stage III melanoma patients is a heterogeneous group with significant OS differences. CLND after positive SLNB might still remain a method of treatment for selected patients with stage III. Monogenic diabetes includes a group of heterogeneous diabetes types. We
Beğen
Yorum Yap
Paylaş
